Nivolumab: as a tool
11 studies: an imaging tracer or a test of drug response. Page 1 of 1. Open to participants first (7), then studies with results posted, then the rest; newest registration first within each.
- Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung CancerNot yet recruitingNCT07892300Early Phase 1Report a problem
- Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)RecruitingNCT07460765Phase 1Report a problem
- Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)RecruitingNCT07210632Early Phase 1Report a problem
- Evaluating PD-1/PD-L1 in Locally Advanced Rectal Cancer by Quantitative Fluorescence Molecular EndoscopyNot yet recruitingNCT06304597Phase 1Report a problem
- Drug Screening Using IMD in Bladder CancerEnrolling by invitationNCT06204614Early Phase 1Report a problem
- Drug Screening Using Novel IMD in Renal Cell CarcinomaRecruitingNCT05700461Phase 1Report a problem
- Implantable Microdevice In Primary Brain TumorsRecruitingNCT04135807Early Phase 1Report a problem
- CIVO Intratumoural Microdosing of Anti-Cancer Therapies in AustraliaWithdrawnNCT04891718Early Phase 1Report a problem
- Intratumoral Microdosing of Motolimod in HNSCCTerminatedNCT04272333Early Phase 1Report a problem
- Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast CancerTerminatedNCT03432741Phase 1Report a problem
- Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue SarcomaCompletedNCT03056599Phase 1Report a problem